论文部分内容阅读
目的:观察吉西他滨固定剂量率输注联合顺铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法:选择10例经病理学或细胞学确诊的晚期NSCLC患者,采用吉西他滨联合顺铂治疗,吉西他滨1000mg/m2用输液泵以固定剂量率10mg/(m2·min)输注,即100min完成静脉滴注,d1和d8;顺铂25mg/m2,连用3d。21d为1个化疗周期。每个化疗周期均评价毒性反应,2个化疗周期后评价疗效。结果:10例患者均出现不同程度的血液学毒性反应及非血液学毒性反应,其中5例发生Ⅲ~Ⅳ度白细胞减少,1例发生Ⅲ度皮疹泛发,3例发生Ⅲ度胃肠道不良反应,2例发生Ⅰ度肝损害,10例患者均未见明显心、肾毒性。4例患者接受2个化疗周期后疗效评价为部分缓解2例,疾病稳定2例,临床获益率为40%。结论:吉西他滨固定剂量率输注联合顺铂治疗晚期NSCLC有效,但可能出现严重的血液学毒性和皮疹泛发,临床上需谨慎选择使用。
Objective: To observe the clinical efficacy and safety of gemcitabine fixed-dose infusion combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Ten patients with advanced NSCLC diagnosed by pathology or cytology were treated with gemcitabine combined with cisplatin. Gemcitabine 1000 mg / m2 was infused intravenously by infusion pump at a fixed dose rate of 10 mg / (m2 · min), ie 100 min Note, d1 and d8; cisplatin 25mg / m2, even with 3d. 21d for a chemotherapy cycle. Toxicity was evaluated in each chemotherapy cycle and evaluated after 2 cycles of chemotherapy. Results: Hematological toxic reactions and non-hematologic toxicities were all observed in 10 patients. Among them, grade Ⅲ ~ Ⅳ leucopenia occurred in 5 cases, generalized Ⅲ degree rash occurred in 1 case, and Ⅲ degree gastrointestinal tract dysplasia in 3 cases Reaction, two cases of grade Ⅰ liver damage occurred, 10 patients were no obvious heart and kidney toxicity. Four patients received two chemotherapy cycles after the evaluation of partial response in 2 cases, 2 cases of stable disease, the clinical benefit rate was 40%. CONCLUSION: Gemcitabine, a combination of fixed-dose infusion and cisplatin, is effective in the treatment of advanced non-small cell lung cancer (NSCLC). However, severe hematological toxicity and generalized rash may occur. Clinicians should be cautiously selected.